A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: a Double-blind, Randomized, Placebo-controlled Study

Overview

Journal Obesity (Silver Spring)

Specialties Endocrinology
Nutritional Sciences
Physiology

Date 2013 Mar 19

PMID 23505169

Citations 26

Authors

Barbara Grube

Pee-Win Chong

Kai-Zhia Lau

Hans-Dieter Orzechowski

Affiliations

Soon will be listed here.

Abstract

Objective: A proprietary natural fiber complex (Litramine IQP G-002AS) derived from Opuntia ficus-indica, and standardized on lipophilic activity, was previously shown in preclinical and human studies to reduce dietary fat absorption through gastrointestinal (GI) fat binding. Here, we investigated the efficacy and safety of IQP G-002AS in body weight reduction.

Design And Methods: One hundred twenty-five overweight and obese adults participated in the study. Subjects were advised on physical activity, and received nutritional counseling, including hypocaloric diet plans (30% energy from fat and 500 kcal deficit/day). After a 2-week placebo run-in phase, subjects were randomized to receive either 3 g/day of IQP G-002AS (IQ) or a placebo. The primary endpoint was change in body weight from baseline; secondary endpoints included additional obesity measures and safety parameters.

Results: One hundred twenty-three subjects completed the 12-week treatment phase (intention-to-treat (ITT) population: 30 male and 93 female; mean BMI: 29.6 ± 2.8 kg/m(2) and age: 45.4 ± 11.3 years). The mean body weight change from baseline was 3.8 ± 1.8 kg in IQ vs. 1.4 ± 2.6 kg in placebo (P < 0.001). More IQ subjects lost at least 5% of their initial body weight compared to placebo (P = 0.027). Compared with placebo, IQ also showed significantly greater reduction in BMI, body fat composition, and waist circumference. IQ was well tolerated with no adverse reactions reported.

Conclusions: These results suggest that the natural fiber complex Litramine IQP G-002AS is effective in promoting weight loss.

Citing Articles

Methodological insights into intervention and outcomes in randomised controlled trials of herbal medicine for obesity: a scoping review.

Chan J, Lau M, Muhamad Rosli S, Mustapha Kamal S, Wan Seman W, Ali N Ther Adv Chronic Dis. 2025; 16:20406223241310206.

PMID: 39917276 PMC: 11795625. DOI: 10.1177/20406223241310206.

Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities.

Van Hul M, Neyrinck A, Everard A, Abot A, Bindels L, Delzenne N Clin Microbiol Rev. 2024; 37(3):e0004523.

PMID: 38940505 PMC: 11391702. DOI: 10.1128/cmr.00045-23.

Usefulness of spp. on the Management of Obesity and Its Metabolic Co-Morbidities.

Gomez-Garcia I, Fernandez-Quintela A, Gonzalez M, Gomez-Zorita S, Muguerza B, Trepiana J Nutrients. 2024; 16(9).

PMID: 38732528 PMC: 11085070. DOI: 10.3390/nu16091282.

A genomics perspective of personalized prevention and management of obesity.

Gkouskou K, Grammatikopoulou M, Lazou E, Vasilogiannakopoulou T, Sanoudou D, Eliopoulos A Hum Genomics. 2024; 18(1):4.

PMID: 38281958 PMC: 10823690. DOI: 10.1186/s40246-024-00570-3.

Seed Extract with Standardized Content of 6-Paradol Reduces Visceral Fat and Enhances Energy Expenditure in Overweight Adults - A Randomized Double-Blind, Placebo-Controlled Clinical Study.

Venkataramana Sudeep H, Aman K, Jestin T, Shyamprasad K Drug Des Devel Ther. 2022; 16:3777-3791.

PMID: 36329722 PMC: 9624637. DOI: 10.2147/DDDT.S367350.

References

Finucane M, Stevens G, Cowan M, Danaei G, Lin J, Paciorek C . National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011; 377(9765):557-67. PMC: 4472365. DOI: 10.1016/S0140-6736(10)62037-5. View

Simon G, Ludman E, Linde J, Operskalski B, Ichikawa L, Rohde P . Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry. 2008; 30(1):32-9. PMC: 2675189. DOI: 10.1016/j.genhosppsych.2007.09.001. View

Bray G, Paeratakul S, Popkin B . Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav. 2004; 83(4):549-55. DOI: 10.1016/j.physbeh.2004.08.039. View

Stevens G, Mascarenhas M, Mathers C . Global health risks: progress and challenges. Bull World Health Organ. 2009; 87(9):646. PMC: 2739926. DOI: 10.2471/blt.09.070565. View

Hammond R, Levine R . The economic impact of obesity in the United States. Diabetes Metab Syndr Obes. 2011; 3:285-95. PMC: 3047996. DOI: 10.2147/DMSOTT.S7384. View

Cavaliere H, Floriano I, Medeiros-Neto G . Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 2001; 25(7):1095-9. DOI: 10.1038/sj.ijo.0801645. View

Johansson K, Neovius K, DeSantis S, Rossner S, Neovius M . Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009; 10(5):564-75. DOI: 10.1111/j.1467-789X.2009.00581.x. View

Van Gaal L, Broom J, Enzi G, Toplak H . Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol. 1998; 54(2):125-32. DOI: 10.1007/s002280050433. View

Trumbo P, Schlicker S, Yates A, Poos M . Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002; 102(11):1621-30. DOI: 10.1016/s0002-8223(02)90346-9. View

10.

de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P . Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010; 178(2):230-5. DOI: 10.1016/j.psychres.2009.04.015. View

11.

Wadden T, Stunkard A . Social and psychological consequences of obesity. Ann Intern Med. 1985; 103(6 ( Pt 2)):1062-7. DOI: 10.7326/0003-4819-103-6-1062. View

12.

Fry J, Finley W . The prevalence and costs of obesity in the EU. Proc Nutr Soc. 2005; 64(3):359-62. DOI: 10.1079/pns2005443. View

13.

Davidson M, Hauptman J, DIGIROLAMO M, Foreyt J, Halsted C, Heber D . Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999; 281(3):235-42. DOI: 10.1001/jama.281.3.235. View

14.

Simon G, Von Korff M, Saunders K, Miglioretti D, Crane P, van Belle G . Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006; 63(7):824-30. PMC: 1913935. DOI: 10.1001/archpsyc.63.7.824. View

15.

Collazo-Clavell M . Safe and effective management of the obese patient. Mayo Clin Proc. 1999; 74(12):1255-9; quiz 1259-60. DOI: 10.4065/74.12.1255. View

16.

Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H . Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998; 352(9123):167-72. DOI: 10.1016/s0140-6736(97)11509-4. View

17.

Drent M, van der Veen E . Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord. 1993; 17(4):241-4. View

18.

Hauptman J, Lucas C, Boldrin M, Collins H, Segal K . Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000; 9(2):160-7. DOI: 10.1001/archfami.9.2.160. View

19.

Jull A, Rodgers A, Walker N . Honey as a topical treatment for wounds. Cochrane Database Syst Rev. 2008; (4):CD005083. DOI: 10.1002/14651858.CD005083.pub2. View

20.

Phelan S, Wadden T, Berkowitz R, Sarwer D, Womble L, Cato R . Impact of weight loss on the metabolic syndrome. Int J Obes (Lond). 2007; 31(9):1442-8. DOI: 10.1038/sj.ijo.0803606. View